Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVM18001 in Active Refractory Systemic Lupus Erythematosus, Myasthenia Gravis and Scleroderma
NCT07470151Phase 1Recruiting
- Start
- Mar 2026
- Primary completion
- Nov 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EVM18001 in systemic lupus erythematosus (SLE), myasthenia gravis (MG) and scleroderma. Primary endpoints: Adverse Events and Serious Adverse Events, Recommended Dose for Subsequent Treatment and 5 more. Started Mar 2026; status: recruiting.
02
Drugs
EVM18001
03
Conditions
systemic lupus erythematosus (SLE)myasthenia gravis (MG)scleroderma
Beyond the preview
Go deeper on NCT07470151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07470151.